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Abstract
Despite the significant contributions of immunocompetent mouse models to the development and assessment of cancer 
immunotherapies, they inadequately represent the genetic and biological complexity of corresponding human cancers. 
Immunocompromised mice reconstituted with a human immune system (HIS) and engrafted with patient-derived tumor 
xenografts are a promising novel preclinical model for the study of human tumor-immune interactions. Whilst overcoming 
limitations of immunocompetent models, HIS-tumor models often rely on reconstitution with allogeneic immune cells, mak-
ing it difficult to distinguish between anti-tumor and alloantigen responses. Models that comprise of autologous human tumor 
and human immune cells provide a platform that is more representative of the patient immune-tumor interaction. However, 
limited access to autologous tissues, short experimental windows, and poor retention of tumor microenvironment and tumor 
infiltrating lymphocyte components are major challenges affecting the establishment and application of autologous models. 
This review outlines existing preclinical murine models for the study of immuno-oncology, and highlights innovations that 
can be applied to improve the feasibility and efficacy of autologous models.
Keywords Autologous models · Animal models · Immunotherapies · Cancer · Immune-system · Preclinical Safety-
assessment/risk management
Abbreviations
ACT  Adoptive cell therapy
ALI  Air liquid interface
BM  Bone marrow
CAR  Chimeric antigen receptor
CAF  Cancer-associated fibroblasts
CAR-M  CAR-macrophages
CDX  Cell derived xenograft
CRS  Cytokine release syndrome
FFPE  Formalin fixed paraffin embedded
FL  Fetal liver
GEMM  Genetically engineered mouse model
GM-CSF  Granulocyte–macrophage colony-stimulat-
ing factor
GvHD  Graft versus host disease
HIS  Human immune system
HLA  Human leukocyte antigen
HSC  Hematopoietic stem cells
Hu-BLT  Human bone marrow, liver, thymus
Hu-CDX  Humanized CDX
Hu-PBL  Human peripheral blood lymphocytes
Hu-PDX  Humanized PDX
Hu-SRC  Human stem repopulating cells
ICI  Immune checkpoint inhibitors
IL-3  Interleukin 3
IL-6  Interleukin 6
IO  Immuno-oncology
IRAE  Immune-related adverse event
MHC  Major histocompatibility complex
MSC  Mesenchymal stem cells
NK  Natural killer
NOD  Non-obese diabetic
NSG  NOD.Cg-Prkdcscid Il2rgtm1Wjl /SzJ
NSG-dKO  NSG-(Kb Db)null(IA)null
NSG-IL15  NSG interleukin 15
NSG-SGM3  NSG tg expression KITLG, CSF2 and IL-3
NT  Neurotoxicity
OS  Overall survival
PBMC  Peripheral blood mononuclear cells
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PD-1  Programmed cell death protein 1
PD-L1  Programmed death ligand 1
PDO  Patient derived organoids
PDX  Patient derived xenograft
SCF  Skp1-Cullin-F-box protein
SPMC  Splenic mononuclear cells
TAM  Tumor associated macrophages
TCR  T-cell receptor
TIL  Tumor infiltrating lymphocyte
TLS  Tumor lysis syndrome
TME  Tumor microenvironment
UBC  Umbilical cord blood
VEGF  Vascular endothelial growth factor
Introduction
Immuno-oncology (IO) research has shaped our modern 
understanding of cancer progression, illuminating the para-
doxical role of immune cells in both the induction and elimi-
nation of cancer. Throughout the stages of tumor develop-
ment, cancer cells evolve to evade destructive immunity, 
employing mechanisms that mimic peripheral immune tol-
erance [1]. Cancer associated inflammation is present at all 
stages and has been shown to contribute to genomic insta-
bility, angiogenesis, epigenetic modifications, induction of 
cancer cell proliferation and enhancement of anti-apoptotic 
pathways [2]. Emerging immunotherapies, such as immune 
checkpoint inhibitors (ICI) (see Glossary) and Adoptive Cell 
Therapy (ACT), aim to treat cancer through the activation 
and enhancement of anti-tumor immunity [3]. Immunothera-
pies have significantly improved overall survival (OS) in a 
wide variety of cancer types, yet immunotherapeutic agents 
have a notably higher rate of failed clinical trials in compari-
son to alternative cancer therapeutics [4]. Preclinical assess-
ment of the safety and toxicity of immunotherapies is heav-
ily reliant on in vivo immunocompetent mouse models that 
show poor translation of beneficial responses to the clinic. 
Furthermore, the complex heterogeneity of immune systems, 
both between and within patients over time, significantly 
impacts the effectiveness and safety of approved immuno-
therapeutic agents [5]. Immunotherapies have been linked 
to numerous immune related adverse events (IRAEs) such 
as cytokine release syndrome (CRS), pneumonitis, and neu-
ropathy, in addition to late onset rheumatic diseases [6–9]. 
These IRAEs range from mild to severe and are thought to 
be linked to inflammatory damage consequent to non-spe-
cific activation of the immune system. There is a clear need 
for well-designed in vitro and in vivo preclinical platforms 
that can accurately assess both the efficacy and safety of 
novel agents and individual responses to immunotherapies.
Human immune system (HIS) mouse models are increas-
ingly being combined with human xenograft models for the 
investigation of human immune cell behavior in response 
to tumors and therapeutics [10, 11]. Most notably, HIS 
patient-derived xenograft (hu-PDX) models have been uti-
lized to assess efficacy and toxicity of immunotherapies in 
the treatment of a variety of tumor types [12, 13]. How-
ever, the rate of successful engraftment is highly variable 
and it can take at least 3 months to develop an experimental 
cohort [14]. Patient-derived organoids (PDOs) are emerg-
ing as suitable alternatives, retaining the complexity of the 
original tumor, and showing quicker and more successful 
establishment than traditional PDXs [15, 16]. Furthermore, 
preclinical HIS-tumor models often rely on allogeneic lym-
phocytes from donated fetal liver (FL), bone marrow, cord 
blood or peripheral blood mononuclear cells (PBMCs) for 
immune reconstitution [10]. This allogeneic reconstitution 
is not representative of the clinical scenario and can lead to 
difficulties distinguishing between anti-tumor and alloim-
mune responses.
Models that integrate autologous patient-derived tumor 
and immune cells can provide a more individualized plat-
form for IO research. Emerging autologous HIS models have 
shown promise as a valuable tool for the mechanistic and 
preclinical study of approved and novel immunotherapies 
[17–21]. The use of autologous models is currently hindered 
by four key challenges: access to autologous tissues, immune 
reconstitution in vivo, Modeling of the entire tumor micro-
environment (TME) and Modeling longitudinal therapeutic 
responses. This review will outline existing and emerging 
in vivo platforms for the preclinical testing of immunothera-
pies. Moreover, the key challenges to establishing autolo-
gous models will be addressed, with potential solutions 
offered to increase their feasibility and applicability.
Murine IO models
Immunocompetent mouse models
Preclinical study of immune-tumor interactions is largely 
dominated by immunocompetent murine models in the form 
of carcinogen-induced, syngeneic, or genetically engineered 
mouse models (GEMMs) (Fig. 1, Table 1). Carcinogen-
induced mouse models are established through the admin-
istration of cancer-causing agents, such as chemicals and 
biological toxins, and best reflect spontaneous tumor forma-
tion for the study of therapeutic effects of tumor initiation, 
promotion, and progression [22, 23]. Carcinogenesis models 
have contributed greatly to our understanding of immune 
surveillance and mechanisms of immune editing [24]. How-
ever, the use of carcinogens to promote cancer development 
can lead to severe DNA damage, resulting in the accumula-
tion of somatic mutations. Furthermore, most human can-
cers do not arise in response to carcinogen exposure alone 
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[25]. Autochthonous tumor formation can also be mod-
eled with GEMMs through either promotion of oncogene 
expression or deletion of tumor suppressors [26]. GEMMs 
allow for the Modeling of tumor tissue in both a cancerous 
and pre-cancerous form and can provide great insights into 
the immunobiology of cancers. However, the spontaneous 
nature of tumor formation seen in both carcinogen-induced 
and GEMM models can be difficult to monitor and require 
large cohorts to produce meaningful data due to the high 
variability in tumor formation and progression [22]. For 
example, the  p53−/− mouse can take more than 7 months 
to form primary tumors and show morbidities soon after 
formation, limiting opportunities for the evaluation of novel 
therapeutics [27]. Furthermore, GEMMs do not recapitu-
late the entire multistep tumorigenesis seen in humans [28], 
often having only two driver mutations [25].
In contrast, in syngeneic models, wild type mice are trans-
planted with spontaneous, carcinogen-induced, or transgenic 
tumor cells established in syngeneic inbred mouse strains, 
allowing for low-cost establishment of large experimental 
cohorts [26, 29]. The lack of rejection in these models also 
allows for the longitudinal study of tumor survival, growth, 
and metastasis. Despite these strengths, choice of syngeneic 
strain and tumor induction methodology has been shown 
to alter tumor immunophenotypes, treatment response 
and mutational burden within the same cancer types [30]. 
Inconsistencies between these models can make it difficult 
to distinguish clinically relevant data from technique-related 
artifacts, hindering the development and validation of novel 
therapeutics. The utility of immunocompetent mouse mod-
els is further diminished by their dependence on murine 
tumor tissue and murine immune compartments. Beneficial 
responses seen in preclinical murine models have thus rarely 
translated to a clinical setting. This is likely to be due to 
the differences between human and mice tumor biology, as 
well as the alignment of protein expression and signaling of 
their respective immune systems [26, 31]. Reconstitution of 
immunocompromised mice with a HIS is therefore increas-
ingly being used as an alternative tool for the study of human 
immune tumor interactions.
Human immune reconstitution
HIS models reconstitute immunocompromised mice, most 
commonly NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) strains 
[32], with a human-derived immune compartment. There are 
Fig. 1  Schematic showing the generation of common preclinical 
murine cancer models. a. Carcinogen-Induced models are generated 
through the administration of cancer-causing agents to immuno-
competent mouse strains. b. GEMMs promote tumor development 
through the promotion of oncogene expression or through deletion 
of tumor suppressors. c. Syngeneic models are generated through 
administration of murine-derived tumor cell lines, commonly car-
cinogen-induced cancers or transgenic tumor lines. d. CDX models 
are established through transplantation of human-derived 2D cancer 
cells into immunocompromised mice, either subcutaneously (under 
the skin) or orthotopically (in the corresponding organ). e. PDX mod-
els are established by transplantation of whole patient-derived tumor 
tissue either subcutaneously or orthotopically into immunocompro-
mised mice, followed by in  vivo passage of the tissue to create an 
experimental cohort
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currently three established HIS platforms; human Peripheral 
Blood Lymphocytes (hu-PBL), human Stem Repopulating 
Cell (hu-SRC) and human Bone marrow, Liver Thymus (hu-
BLT) model (Fig. 2). Curran et al. review outlines these 
platforms, their pathology and application to the field of IO 
[10]. In short, in the hu-SRC model, mice are humanized 
through the engraftment of  CD34+ve hemopoietic stem cells 
(HSCs) obtained from bone marrow (BM) [33], umbilical 
cord blood (UCB) [34] or FL [35]. This model leads to 
engraftment of a diverse repertoire of immune cells, includ-
ing B- and T-cells, with improved reconstitution when using 
UCB or FL derived HSCs in newborn rather than adult mice 
Table 1  In vivo preclinical models for Immunotherapy
Model Advantages Limitations References
Immunocompetent models
Carcinogen-induced models:
Tumor bearing mice induced after
administration of carcinogen
 + Sporadic cancer development
 + High heterogeneity
 + Natural tumor microenvironment
 + Tumors develop from normal cells
 + Easy to work with
 + A wide range of methodologies can be 
incorporated to induce tumors
‒ Difficult to monitor tumor growth
‒ Variability in tumor progression and 
high heterogeneity
‒ Large cohorts needed for data interpre-
tation
‒ Do not mimic tumor formation from 
chronic inflammation
‒ Severe DNA damage




Tumor bearing mice established through
genetic manipulation of cancer causing
genes
 + Natural tumor microenvironment
 + Tumors development from normal cells
 + Modeling cancer at a variety of stages
‒ Low immunogenicity
‒ Difficult to monitor tumor growth
‒ Lengthy and variable tumor progres-
sion






Tumor bearing mice established through
injection of murine cancer cell lines
 + Reproducible
 + Easy establishment of large cohorts
 + Accurate tumor monitoring
 + Non-immunogenic
 + Low cost
‒ Lack of native tumor microenvironment
‒ Methodology linked alteration of 
immunophenotype
‒ Lack heterogeneity




Immunocompromised mice bearing 
human
tumor cell line xenograft and reconstituted
with a HIS
 + High engraftment rates and reproduc-
ibility
 + Inexhaustible tumor source
 + Potential for metastasis when trans-
planted orthotopically
 + CDX models of a variety of tumor 
types readily available commercially
‒ Highly selective in vitro expansion 
resulting in genetic and phenotypic
aberrations
‒ Low predictive power and correlation 
to clinical results





Immunocompromised mice bearing whole
tissue human tumor xenografts and
reconstituted with a HIS
 + Retention of tumor cell heterogeneity 
and stromal tissue (at low
passages)
 + Reproduces the complexity of the origi-
nal tumor and immune system
 + Have been established for a wide vari-
ety of tumor types, including drug
refractory tumors
 + Allogeneic models readily available 
commercially
‒ Low tumor engraftment success rate 
(approximately 49%)
‒ Engraftment favors aggressive tumors
‒ Long establishment times (at least 
3 months)
‒ Low rates and duration of immune 
reconstitution (dependant on humaniza-
tion
method)





Immunocompetent mice bearing human
Tumor xenograft and HIS and adminis-
tered
a CAR therapeutic
 + Recapitulate post treatment immune 
changes
 + Measure CAR mediated killing (both 
direct and indirect via activation of
resident immune cells)
 + Facilitates the design of new CAR 
therapeutics
‒ Limited IL-6 expression in these 
models
‒ Rapid onset of GvHD
‒ Not able to model resistance over time
[17, 18, 63]
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[36]. However, this model typically takes 16 weeks to be 
established, displays a lack of human educated T-cells and is 
heavily reliant on pre-experimental sub-lethal γ-irradiation 
to facilitate engraftment [37]. In comparison hu-BLT mod-
els are established through the surgical transplantation of 
human FL and thymus fragments under the kidney capsule 
of immunocompromised mice. The presence of autologous 
thymic tissue allows for better T-cell development and edu-
cation, in addition to supporting a more diverse immune 
lineages of B-cells, monocytes, macrophages and dendritic 
cells [38, 39]. A consequence of the T-cells maturing in the 
fetal thymus is the development of graft versus host disease 
(GvHD), in which maturing T-cells attack the mouse tis-
sue, shortening the experimental window to approximately 
20 weeks [40]. This immune attack on the mouse is avoided 
in the hu-SRC model, as human T-cells are educated by the 
mouse thymus with negative selection of T-cells most likely 
to attack mouse antigens [41]. However, this education of 
human T-cells against antigen presented by mouse thymic 
epithelial cells can make the hu-SRC model unsuitable for 
the study of immunotherapies with T-cells largely unable to 
recognize and bind to potential human antigen present by 
human (rather than mouse) antigen presenting cells [42].
The hu-PBL models are the simplest and most cost-effi-
cient method of humanization, engrafting immunocompro-
mised mice with mature human leukocytes isolated from 
peripheral blood, spleen or lymph nodes. As human leuko-
cytes inoculated in this model are already mature, human-
ized mice can be established quickly with a predominant 
reconstitution of  CD3+ve T-cells with an activated/effector 
phenotype [10]. The engraftment kinetics of the hu-PBL 
model make it best suited for the study of mature immunity, 
such as identification of T-cell clones responsive to tumor 
neoantigens [43]. The hu-PBL model can also produce more 
appropriate tumor-immune interactions, as T-cells educated 
within a human environment are more likely to recognize 
and bind to MHC proteins on the implanted human tumor 
[44]. However, the presence of mature T-cells significantly 
shortens the experimental window with this model, rapidly 
inducing GvHD [45]. Despite these limitations, hu-PBL 
models are the most feasible humanization method for estab-
lishing autologous HIS-tumor models for adult patients and 
show promise as a predictive model of patient response rates 
[43].
Humanized CDX models
Cell line-derived xenograft (CDX) models establish a tumor 
bearing system in vivo through implantation of immunocom-
promised mice with cell lines derived from primary tumor 
tissue. CDX bearing HIS mice (hu-CDX) have been utilized 
to investigate tumor-immune compartment interactions, as 
well as for the generation of novel cancer immunotherapies 
[46]. Rios-Doria et al.utilized  CD34+ve humanized NSG 
mice transplanted with different cancer lines to demonstrate 
that TIL populations were influenced by tumor type and not 
by donor. Furthermore, the study demonstrated that cancer 
cell lines expressed programmed death ligand 1 (PD-L1), 
while they showed efficacy of the anti PD-L1 therapeutic 
agent, atezolizumab, in their hu-CDX model [13]. Other 
studies have utilized hu-CDX mice to interrogate efficacy of 
bi-specific antibodies for targeting T-cells to a tumor antigen 
[47–49] or use of adoptive natural killer (NK) cell therapy 
either alone or in combination with therapeutic antibodies 
to target tumors [50, 51].
Hu-CDX models are an attractive preclinical tool as the 
xenotransplantation of human cell lines is easy to control, 
well established and allows for rapid evaluation of therapeu-
tic agents. However, preclinical studies using hu-CDXs are 
not able to predict treatment safety and efficacy in humans, 
with failures in clinical trials linked to the genetic homoge-
neity of the two-dimensional (2D) cell lines used in these 
models [25]. 2D cells implanted in vivo often do not reca-
pitulate the biological properties and behavior of the origi-
nal tumor, with differences in metastasis, TME and immune 
infiltration [52, 53]. The unrepresentative nature of cell line 
xenografts was highlighted in Daniel et al.’s CDX model of 
small cell lung cancer (SCLC). In this study, tumor-specific 
genes expressed in primary SCLC tissue were lost through-
out cell culture and not regained in vivo, with significant 
implications for preclinical drug screening using these mod-
els [54]. The lack of translational results seen in hu-CDXs 
has driven the adoption of models that can better retain the 
complexity of the parental tumor, such as patient derived 
xenografts (PDXs).
Humanized PDX models
PDXs are established from surgically dissected tumor frag-
ments directly engrafted, subcutaneously or orthotopically, 
into immunocompromised mice (Fig. 2). Compared to 2D 
tumor cell lines, these models better reproduce the com-
plexity of human cancer, preserving biological and his-
topathological features of the original tumors [14]. PDX-
bearing HIS mice (hu-PDX) have emerged as a platform 
to evaluate the efficacy of immunotherapies in a range of 
tumor types. For example, human anti-carbonic anhydrase 
IX (anti-CAIX) antibodies have been shown to promote 
immune-mediated tumor killing in a PBMC humanized hu-
PDX model of renal cell carcinoma (RCC) [55]. Combina-
tion therapies have also been evaluated in hu-PDXs, such as 
CTLA-4 blockade and the oncolytic vaccinia virus (VACV) 
therapy [56]. PDXs can survive in vivo with an allogeneic 
immune compartment, however immune reconstitution with 
different donors has been shown to alter treatment response 
in the same PDX tumor bearing mice [57]. Ideally, hu-PDX 
2742 Cancer Immunology, Immunotherapy (2021) 70:2737–2750
1 3
2743Cancer Immunology, Immunotherapy (2021) 70:2737–2750 
1 3
models should be generated with the HIS and tumor derived 
from the same donor, allowing the assessment of therapeu-
tics in the context of the patient’s own immune system. 
However, poor tumor implantation success rates and limited 
access to patient immune samples are two major limitations 
of this approach (Table 1) that often make autologous recon-
stitution unfeasible.
Consequently, the tumor and immune cells used in this 
model are usually obtained from different, or partially 
human leukocyte antigen (HLA) matched, donors. Although 
these studies can be very informative, variations in the anti-
tumor immune response from different donors to the same 
PDX tumor, due to an underlying allogeneic response, can 
complicate data interpretation [57]. Recent studies have uti-
lized tumor infiltrating lymphocytes (TILs) as an autologous 
source for immune reconstitution, developing autologous hu-
PDX models for the study of immunotherapies [20, 21]. For 
example, Jespersen et al.modeled ACT and anti-PD1 immu-
notherapy in hu-PDX mice reconstituted with autologous 
TIL-derived T-cells and reported response rates that cor-
related with clinical outcomes. This study also highlighted 
the need for repeated administration of IL-2 for T-cells 
to effect tumor eradication, even in the presence of PD-1 
antibodies [20]. Hu-PDX models have also been utilized 
in the field of Allergo-Oncology, which is concerned with 
immune and allergic responses in cancer [58]. For example, 
in a hu-PDX model of ovarian cancer, IgE antibodies were 
used to prime tumor associated macrophages (TAMs) to 
elicit effector responses and restrict tumor proliferation [59, 
60]. Whilst further comparisons of hu-PDX models is war-
ranted, emerging autologous hu-PDXs show the value of 
autologous reconstitution in preclinical models, recreating 
the anti-tumor effects observed in patients.
Humanized CAR models
Chimeric antigen receptor (CAR) T-cell therapy aims to acti-
vate anti-tumor immunity through reprogramming a patient’s 
immune effector cells to recognize tumor surface antigens. 
Patient-derived T-cells are transduced, often through len-
tiviral vectors, with a construct containing a single chain 
variable fragment (scFv), transmembrane domain, co-
stimulatory molecule and stimulatory molecule [61]. Two 
CAR T-cell therapies have been approved for clinical use 
(Kymriah™ and Yescarta™), both of which target CD19-
expressing tumor cells for use in acute lymphoblastic leu-
kemia and B-cell Lymphomas [62]. Both Kymriah™ and 
Yascarta™ have shown significant lifesaving potential in 
otherwise incurable cases, although patients must be closely 
monitored for severe treatment linked toxicities such as 
CRS, neurotoxicity (NT) and tumor lysis syndrome (TLS) 
[63]. Furthermore, resistance often occurs in these patients 
only months after treatment [63–65]. Therefore, further 
research is essential to understand the mechanisms of treat-
ment resistance and toxicities, and to develop novel CAR 
T-cell therapies. Emerging autologous HIS models are a 
highly valuable tool for mechanistic and preclinical study of 
CAR T-cell therapies, avoiding anti-mouse xenoantigens and 
allogeneic responses [17]. For example, Jin et al. recently 
developed an autologous HIS mouse model of anti-CD19 
CAR-T cell therapy, in which immunocompromised NSG 
mice were reconstituted with a functional human immune 
system that was genetically matched to B-lymphoblastic leu-
kemia (B-ALL) [18]
Whilst CAR-T cell therapies have shown great promise 
for treating hematological cancers, they are limited in their 
ability to reach solid tumors due to a broad array of immune 
obstacles. TAMs naturally traffic to tumors and may be able 
to overcome the barriers CAR-T cells face. Novel CAR-Mac-
rophages (CAR-Ms) are being developed and modeled in 
HIS mice for the treatment of solid tumors. Klichinsky et al. 
tested anti-tumor activity of a CAR-M to implanted SKOV3 
tumor cells in  CD34+ve HSC humanized NSG mice [64]. In 
this model, CAR-Ms from a male donor and HSCs from a 
female donor were used to correctly distinguish HSC and 
CAR derived Macrophages. CAR-Ms were shown to boost 
anti-tumor T-cell activity and illicit a pro-inflammatory 
response within the TME through expression of M1 asso-
ciated interferon genes [64]. Humanized models can thus 
Fig. 2  Steps involved in establishing human immune system (HIS) 
models in vivo: a. The hu-PBL (human Peripheral Blood Leuko-
cytes) model can be established through intravenous (IV) or Intra-
peritoneal (IP) injection of human peripheral blood mononuclear 
cells (PBMCs) in adult immunocompromised mice. b. The hu-SRC 
(human Stem Repopulating Cell) model is established through either 
IV or intrafemoral (IF) injection of haematopoietic stem cells (HSCs) 
into irradiated adult immunocompromised mice. HSCs are isolated 
from either umbilical cord blood, bone marrow (BM), fetal liver or 
mobilized peripheral blood HSCs. Hu-SRC models can also be estab-
lished through IV, intracardiac (IC) or intrahepatic (IH) injection of 
HSCs into irradiated newborn immunocompromised mice. c. The hu-
BLT (human Bone marrow, Liver, Thymus) model can be established 
through the transplantation of foetal thymus and liver fragments 
under the kidney capsule of irradiated adult immunocompromised 
mice, in addition to the IV injection of autologous HSCs. d. The hu-
PDX (HIS patient-derived xenograft) model dually engrafts immuno-
compromised adult mice with early passage PDXs and a HIS. Most 
commonly, this is done with the use of immunocompromised mice 
engrafted with human  CD34+ve HSCs but can also be established 
with human lymphocytes such as PBMC or splenic mononuclear cells 
(SPMCs). e. Schematic showing the development of preclinical mod-
els for the in vivo assessment of cancer immunotherapies. Primary 
tumor tissue from the patient can be used to derive 2D cell lines and 
PDOs. A biopsy of primary tissue can also be expanded in vivo in 
immunocompromised mice to establish a PDX line. Patient derived 
(autologous) or allogeneic PBMCs, SPMCs or HSCs can be used to 
generate humanized mice. 2D cells, 3D cells or passaged xenograft 
tissue can be implanted or injected into the established HIS mice. 
Both HIS mice and tumor bearing HIS mice can be used to study cell 
fate, functional efficacy and safety and toxicity of immunotherapies.
◂
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enable preclinical validation of CAR therapeutics. However, 
studying therapy toxicity in HIS models is still limited due 
to undetectable IL-6 levels in mice, with IL-6 being a known 
driving force for CRS [17]. Furthermore, the onset of GvHD 
limits the evaluation of treatment resistance over time. Since 
both toxicity and relapse are of great concern when choos-
ing a treatment plan, there remains an urgent unmet need for 
preclinical models that can more accurately recapitulate the 
clinical response.
Autologous IO models: limitations 
and innovations
Preclinical models utilizing patient derived tissues are 
essential to the advancement of cancer therapeutics, with 
anticipated improved predictive power than classical ani-
mal models. Autologous models, using tumor and immune 
compartments from the same patient, have great potential 
to better represent patient immune-tumor interactions and 
treatment responses. However, several confounding factors 
hinder the establishment of autologous models, making them 
unfeasible for many researchers. These include poor access 
to autologous tissues, donor- and technique-related variation 
in immune reconstitution, poor representation of the in vivo 
TME and limited ability to model longitudinal responses due 
to a short experimental window. It is important to improve 
access and application of autologous models to truly unveil 
their potential as a preclinical tool. We outline these limita-
tions below and review methodologies that could potentially 
address these challenges (Table 2).
Access to autologous tumor tissue
Matched patient tumor and immune cells is often a scarce 
resource and many researchers rely on archived tissue, 
immortalized cell lines and allogeneic immune cells for 
their studies. Primary tumor tissue and adjacent healthy tis-
sue, although routinely removed during surgical treatment 
of cancer, is usually rapidly formalin-fixed-paraffin-embed-
ded (FFPE) for invaluable diagnostic purposes. Acquiring 
fresh tissue samples requires a high level of collaboration 
to collect limited samples in a timely manner, so as not to 
adversely impact the patient’s treatment or diagnosis. It is 
essential that researchers can utilize the limited supply of 
primary tissue to establish representative preclinical mod-
els. Whilst 2D cell cultures can provide an unlimited supply 
Table 2  Overcoming limitations of preclinical autologous models
Limitation Potential solution Future work References
Access to autologous
Lymphocytes and tumor cells
PBMC and TIL expansion protocols
Use of alternative lymphocyte sources such 
as SPMCs
3D tumor organoids can be used as a sub-
stitute when tumor tissue is limited
Optimization of expansion protocols to 
allow for a greater
lineage of lymphocyte populations
Assessment of humanized PDO (hu-PDO) 
mouse models for the
Preclinical study of immunotherapies
[10, 15, 16, 20, 21, 77]
Limited immune
reconstitution
Preliminary colony-forming assay to assess 
repopulation capacity
Use of patient bone marrow cells when 
possible
Use of novel strains with transgenic 
expression of human
Molecules that promote engraftment of 
human immune
Compartments
Investigate and clarify benefits of novel 
strains in hu-PBL  models
Investigate and clarify disparities in tumor-
immune interactions
When using adult BM cells for immune 
reconstitution
Explore methods of improving engraftment 
success for donors  with low repopulation 
capacity
[10, 19, 81, 82]
Modeling the parental TME Expanding PDXs orthotopically in already 
humanized mice
Injection of PBMC derived MSCs to pro-
mote neovascularization
Complimentary use organoid wholistic 
(ALI), reductionist
(tumor-stromal/immune) and microfluidic 
(‘tumor-on-chip’) coculture systems
Further exploration of the implantation of 
tumor and stromal
PDOs and PDO co-cultures in vivo
[44, 85–91]
Rapid onset of GvHD Novel strains of immunocompromised 
mice with MHC class I
and or II knockout (such as the NSG-dKO 
strain) can be used to lengthen experi-
mental windows
More research needed using MHC 
knockout strains in preclinical study of 
immunotherapies
Exploration of potential cross strains that 
can both improve immune engraftment 
and prolong the experimental window
[77, 92–95]
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of tumor cells, they do not recapitulate the complexity of 
the original tumor [66]. Furthermore, traditional PDX mod-
els can take up a considerable amount of primary tissue to 
establish, with unpredictable rates of successful engraftment 
[14].
Alternatively, three dimensional (3D) cell cultures, such 
as organoids, can be established in a wide range of can-
cer types and have been shown to more closely mimic the 
in vivo tumor biology in terms of histoarchitecture [16, 67], 
mutational landscape [68, 69], signaling [70] and heteroge-
neity [71, 72]. This phenotypic complexity allows for physi-
ological barriers to immune cells and increased resistance to 
cytotoxicity, more closely replicating in vivo tumor-immune 
interactions [73]. Tumor PDOs can be established from a 
small tumor biopsy and have been shown to have a higher 
rate of successful establishment in comparison to PDXs in 
addition to retaining the genetic and phenotypic complexity 
of the parental tumor [15, 16]. Unlike PDXs, organoids can 
be established from both tumor and adjacent healthy tis-
sue, providing autologous healthy organoids that can serve 
as experimental controls. Furthermore, PDOs can be easily 
cryopreserved and utilized for in vitro characterization and 
experimentation, allowing for more freedom in experimental 
design.
Access to autologous immune compartments
PBMCs and TILs are often the only fresh source of autolo-
gous lymphocytes for preclinical models and are ideal for 
the establishment of in vitro co-culture assays, yet provide 
an insufficient cell yield for in vivo experimentation. Due to 
donor variation in the success of human immune engraft-
ment, multiple in  vivo reconstitutions may be required 
to optimize humanization, therefore a plentiful supply of 
immune cells is essential. Ex vivo culture and expansion of 
patient lymphocytes could be used to address this limitation. 
Several expansion protocols are available and can be opti-
mized for individual lymphocyte and monocyte populations, 
maintaining relative phenotypes [65, 74–76]. For example, 
Issa et al.published a protocol for the ex vivo expansion, 
characterization, and in vivo implantation of human regula-
tory T-cells [75]. As mentioned, ex vivo expansion of TILs 
has also been utilized for the establishment of autologous 
hu-PDX models [20, 21]. Gitto et al. achieved an 8–ten-
fold expansion of TILs after 12–14 days consisting of 90% 
 CD3+ve T-cells, 71.2% of which were cytotoxic  CD8+ve 
T-cells [21]. Whilst not representative of the entire immune 
compartment, expansion protocols could allow for more in-
depth exploration of interactions between tumor cells and 
specific immune populations.
In some cancers, additional sources of autologous lym-
phocytes will be available. For example, BM cells may 
be available in patients undergoing BM aspiration and/
or biopsy as part of their treatment. Furthermore, spleen 
mononuclear cells (SPMCs) can be obtained from pan-
creatic cancer patients undergoing surgical resection with 
splenectomy. The spleen is a plentiful resource of autolo-
gous mature lymphocytes, and SPMCs could be used for 
humanization of immunocompromised mice, as in the hu-
PBL model [10]. Recently Matas‐Céspedes et al. assessed 
the efficacy of SPMCs for establishing HIS mice, com-
paring BM, HSC, PBMC and SPMC engraftment from 
the same human donors. They demonstrated that SPMCs 
can be used for the successful engraftment of immune 
cells, showing hCD45 + ve cells in the circulating blood, 
spleen and liver of the mice. Similar to the hu-PBL model, 
engrafted immune cells from SPMC reconstitution was 
mostly T-cells with an effector memory phenotype [77].
Improving immune reconstitution
The hu-PBL model, whilst simple and cost effective, is 
limited to the engraftment of mature T-cells and low lev-
els of B-cells and myeloid cells [78]. Reconstitution of 
immunocompromised mice with BM derived  CD34+ve 
cells has shown systemic repopulation of multiple line-
ages and presents a suitable alternative to the hu-PBL 
model in patients undergoing fibular resection and BM 
aspiration. For example, Fu et al.’s model of head and 
neck squamous cell carcinoma (HNSCC) transplanted 
autologous HNSCC tumor cells and  CD34+ve BM cells 
from HLA-A2+ve patients into NOG-A2+ve mice. In this 
model, both human lymphoid and myeloid cells were 
shown to infiltrate the TME and appropriate populations 
of human T-cells, myeloid cells and NK cells were identi-
fied in the spleen of the mouse [19]. However, the use of 
 CD34+ve cells from adult donors has several limitations 
when compared to  CD34+ve cells derived from umbilical 
cord blood, including lower pluripotency, quiescence and 
lymphopoiesis in addition to poorer engraftment efficacy 
[79, 80]. To improve reconstitution a preliminary colony-
forming unit assay could be used in vitro to discriminate 
donors with higher repopulation capacity, which can then 
be selected for in vivo engraftment of mice. Furthermore, 
variation between experiments can be reduced by selecting 
donors within the same age group, preferable young adults 
(> 35 years old) but mid-age adults (36–61) can also be 
considered [80].
Strains with transgenic expression of human cytokines 
can also be employed to improve immune reconstitution 
through cytokine stimulation of immune cell hematopoie-
sis [10]. For example, NSG-SGM3 mice express human 
cytokines; SCF, GM-CSF and IL3, and have been shown to 
support myeloid and  CD4+ve Treg engraftment in hu-SRC 
models [81]. NSG-IL15 mice were also shown to promote 
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NK survival post HSC engraftment in comparison to NSG 
mice [82]. However further research is required to clarify 
the benefits of these strains in hu-PBL and hu-BLT models.
Modeling the tumor microenvironment
The TME is comprised of a wide range of resident and infil-
trating host cells, secreted factors, and extracellular matrix 
proteins in addition to heterogenous tumor cells. Each com-
ponent of the TME is thought to play a role in tumor forma-
tion and survival. For example, cancer-associated fibroblasts 
(CAFs) have a well-established role in tumor promotion pri-
marily through increasing vascularization and blood flow 
to the TME [83]. Models that fail to account for all com-
ponents of the TME cannot presume to be representative of 
the parental in vivo environment. However, Modeling the 
TME in its entirety remains challenging, with most autolo-
gous models comprising of immune and tumor cells only. 
Human stromal cells present within PDXs are replaced with 
mouse stroma after approximately 3 passages [84]. Retention 
of this parental stromal tissue can be improved by expand-
ing PDXs in already humanized mice, allowing for regu-
lation of xenograft growth by the human immune system 
[44]. Neovascularization could also be promoted in hu-PDX 
models through additional inoculation with peripheral blood 
derived mesenchymal stem cells (MSCs), previously shown 
to upregulate vascular endothelial growth factor (VEGF) in 
NSG mice [85]. The TME can further recapitulated through 
orthotopic transplantation of tumor tissues, which has been 
shown to better retain the parental morphology, molecular 
and pharmacological features in comparison to subcutaneous 
transplantation [86].
Novel in vitro co-culture systems could also be used to 
compliment in vivo models and provide important insights 
into TME biology. PDOs can be easily co-cultured with a 
variety of cell types and can be used to provide insights into 
the role of specific TME compartments, such as CAFs [87]. 
Furthermore, holistic co-cultures can be achieved with the 
use of more complex culturing systems such as air liquid 
interfaces (ALIs). For example, Neal et al. cultured tumor 
biopsies in an ALI, preserving the endogenous immune cell 
population and T-cell receptor (TCR) spectrum for up to 
30 days. Their culture system also allowed Modeling of 
immune checkpoint blockade with subsequent T cell expan-
sion and tumor killing [88]. Microfluidic models, such as 
‘tumor-on-chip’ 3D culturing systems, have also emerged to 
mimic the dynamic in vivo environment more closely. In this 
approach, tumor spheroids are placed within a microfluidic 
device and continuously supplied nutrients and oxygen in 
addition to waste removal [89, 90]. These systems allow for 
study of more complex aspects of the TME, such as chemi-
cal gradients [91].
Modeling longitudinal immunotherapy responses
The main disadvantage of hu-PBL models is the rapid onset 
of GvHD, limiting the experimental window to short term 
studies. Whilst the hu-SRC model has a lower incidence of 
GvHD these models are not efficient for autologous stud-
ies due to their use of HSCs [10]. Novel strains of immu-
nocompromised mice have been developed to delay GvHD 
through elimination of major histocompatibility complex 
(MHC) class I and/or II expression [92–94]. Most recently, 
the use of NSG-(Kb Db)null(IA)null (NSG-dKO) mice, defi-
cient in murine MHC I and II, was shown to significantly 
delay GvHD post PBMC engraftment (up to 125 days) [93] 
and SPMC engraftment (up to 140 days) [77]. This improved 
survival is consistent with xenoreactivity being predomi-
nantly driven by murine MHC class I and II molecules. 
These emerging strains provide a platform for longitudi-
nal evaluation of immunotherapies; however, reconstitu-
tion is still limited to  CD8+ve and  CD4+ve mature T-cells. 
Crossing NSG MHC KO strains with other strains such as 
NSG-SGM3, may both delay GvHD onset and support the 
expression of human cytokines [95], providing a slightly 
more representative in vivo environment.
Conclusions
HIS mouse models, combined with human tumor xenografts, 
are rapidly becoming the gold standard for the preclinical 
assessment of immunotherapeutic agents. The method of 
humanization has significant impacts on the resulting in vivo 
immune repertoire, T-cell functionality and experimental 
window. Therefore, researchers must choose models that best 
align with their research questions. For the establishment 
of mice with autologous human immune cells and tumor 
cells, the hu-PBL appears to be the most feasible and reliable 
choice. Humanized xenograft models, such as hu-PDX and 
hu-CDX, utilize immunocompromised strains to combine 
human tumor and immune compartments. Although hu-
CDX models are attractive for rapid high-throughput screen-
ing, hu-PDX better retain the complexity of human cancer 
showing better translation of results. The key confounding 
factor in these models is the use of allogeneic tumor and 
immune cells, thus results could be misinterpreted due to 
the presence of alloantigen responses.
Models that comprise of an autologous patient derived-
tumor tissue and immune compartment provide a more 
representative system to study tumor-immune interactions 
and patient-specific responses. However, several challenges 
reduce the potential of autologous models. In this review, 
we have outlined how access to autologous tissues can 
be improved with the use of hu-PDOs to retain the com-
plexity of the parental tumor and improve upon the poor 
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engraftment success and long expansion times of traditional 
PDXs. Furthermore, resources of autologous immune com-
partments can be improved with the use of expansion proto-
cols and the use of SPMCs or BM cells in applicable cases. 
The engraftment success of these models can be improved 
with preliminary screening for engraftment efficacy and 
the employment of transgenic strains expressing human 
cytokines. Transgenic strains can also be utilized to improve 
the experimental window of these models. Finally, the TME 
can be better represented in these models through the altera-
tion of PDX expansion and transplantation methodologies, 
the addition of MSCs and the utilization of complimentary 
in vitro 3D co-cultures. Whilst there is no current perfect 
solution, we expect to witness a surge of autologous models 
in the coming years with the fine tuning of these in vitro and 
in vivo methodologies.
Glossary
Adoptive Cell Therapy (ACT)Form of immunotherapy 
that aims to reprogram a patient’s immune system, typically 
T-cells, to recognize and destroy cancer.
Air Liquid Interface (ALI)A method of cell culture 
in which basal stem cells are grown with basal surfaces 
emerged in media, and the apical cellular layer exposed to 
air.
AllogeneicCells taken from different individuals of the 
same species.
AutologousCells taken from the same individual.
Cancer-Associated Fibroblast (CAF)One of the most 
abundant components in the TME.
Chimeric antigen receptor (CAR)A receptor that has 
been designed to bind to tumor specific proteins. CARs are 
added to immune cells, typically patient derived T-cells, to 
help T-cells find and kill tumor cells.
Cell Derived Xenograft (CDX) models inject cell lines 
derived from patient tumor into a mouse.
Cytokine Release Syndrome (CRS)A condition where 
there is a large and rapid release of cytokines into the blood 
as a result of immunotherapy treatment. Symptoms of 
CRS vary in severity from a mild reaction to severe or life 
threatening.
Immune Checkpoint Inhibitors (ICI)Monoclonal 
antibodies that target immune checkpoints to prevent tumor 
immunogenicity. Common targets of ICIs are CTLA-4, PD-1 
and PD-L1.
Graft vs Host Disease (GvHD)A post-transplantation 
condition that occurs when donated tissues or cells see the 
healthy tissues in the recipient’s body as foreign and attack 
them. Typical GvHD symptoms in mice are weight loss, 
hunched posture, and reduced mobility. GvHD can be fatal 
in mice and so when these symptoms reach a certain severity 
the mouse is culled.
Major Histocompatibility Complex (MHC)A group of 
genes that code for proteins found on the surface of cells, 
MHC molecules bind peptide fragments from pathogens 
and display them on the cell surface for T-cell recogni-
tion. MHC molecules can be divided into class I (found on 
almost all cells) and class II (restricted to macrophages and 
lymphocytes).
NOD.Cg-Prkdcscid Il2rgtm1Wjl /SzJ (NSG)Strain of 
immunocompromised mice, developed by the Jackson Lab-
oratory, that lack T-cells, B-cells and NK cells. NSG mice 
carry mutations on the NOD/ShiLtJ genetic background, 
severe combined immune deficiency (scid) mutation in the 
Prkdc protein and a complete null allele of the IL2 receptor 
common gamma chain.
Programmed cell death protein 1 (PD-1)A immune 
checkpoint protein that, alongside its ligand, plays an 
essential role in the inhibition of T-cells within the tumor 
microenvironment.
Patient Derived Organoid (PDO) Organoids derived 
from a patient tumor for in vitro analysis or for transplanta-
tion into a mouse.
Patient Derived Xenograft (PDX) models implant small 
samples of primary human tumor tissue and into an immu-
nodeficient mice for research purposes.
T-Cell Receptor (TCR)A protein complex found on the 
surface of T-cells that is responsible for the recognition of 
antigen-major histocompatibility complex, and initiation of 
inflammatory responses.
Tumor Microenvironment (TME)Includes heteroge-
nous tumor cells in addition to resident and infiltrating host 
cells, blood vessels, secreted factors and extracellular matrix 
proteins within and surrounding the tumor site.
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